Stay updated with breaking news from Between Dicerna. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dicerna Pharmaceuticals, Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended , in connection with Novo Nordisk’s cash tender... | December 25, 2021
Press release content from Business Wire. The AP news staff was not involved in its creation.
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of sto...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million RP Management, LLCApril 8, 2021 GMT Dicerna to receive $180 million upfront and up to $60 million in potential additional milestone payments NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) today announced that Royalty Pharma has acquired Dicerna’s royalty interest in OXLUMO...
Search jobs Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 31,875 shares of common stock and 7,125 restricted stock units (“RSUs”) to be distributed to one new employee with a grant dat...